When was Awen Oncology founded?

Awen Oncology was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is Awen Oncology located?

Awen Oncology is headquartered in Anglesey, United Kingdom.

Who is the current CEO of Awen Oncology?

Ramsay McFarlane of Awen Oncology. They have also founded 1 company.

How many employees does Awen Oncology have?

As of Jun 30, 2026, the latest employee count at Awen Oncology is 8.

Is Awen Oncology a funded company?

Awen Oncology is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 23, 2024.

When was the latest funding round of Awen Oncology?

Awen Oncology's latest funding was a $***** Seed round on Apr 23, 2026, with participation from 1 investor. Its primary sector is Oncology. In United Kingdom, the Oncology sector has seen $511M in funding in 2026 to date.

Where does Awen Oncology rank among its competitors?

Awen Oncology ranks 1688th amongst 3304 active competitors, of which 1117 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Awen Oncology?

Awen Oncology's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Awen Oncology - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for cancer indications. It offers therapeutics that target rare and undrugged cancer-specific factors based on methodology that combines high-throughput cell and molecular biology with advanced computational techniques.

Key Metrics

Founded Year

2021

Location

Anglesey, United Kingdom

Stage

Seed

Latest Funding Round

Seed, Apr 23, 2026, $*****

Investors

Development Bank of Wales & 2 more

Ranked

1688^th among 3304 active competitors

Employee Count

8 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2984 more

View Awen Oncology's full profile

Awen Oncology has raised funding over 2 rounds. Its first funding round was on Aug 23, 2024. Its latest funding round was a Seed round on Apr 23, 2026 for $*****. 1 investor participated in its latest round. Awen Oncology has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Awen Oncology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 23, 2026	1828020	Seed	6528575	2906921	1789446	2837347
Aug 23, 2024	3838892	Seed	6387179	9179258	6823901	Development Bank of Wales & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Awen Oncology's funding rounds and investors

The founders of Awen Oncology are Ramsay McFarlane, Jane Wakeman and Andrea Brancale. Ramsay McFarlane is the CEO of Awen Oncology.

Here are the details of Awen Oncology's key team members:

Ramsay McFarlane: Co-Founder & CEO of Awen Oncology.
Jane Wakeman: Co-Founder of Awen Oncology.
Andrea Brancale: Co-Founder of Awen Oncology.

View details of Awen Oncology's Founder profiles and Board Members

Awen Oncology's employee count trend

Awen Oncology has 8 employees as of Jun 26. Here is Awen Oncology's employee count trend over the years:

Uncover Awen Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Awen Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Awen Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1688th	Awen Oncology 2021, Anglesey (United Kingdom), Seed	Developer of therapeutics for cancer indications	-	Development Bank of Wales, Start Codon & 1 others	31/100